SK Bioscience Co Ltd
KRX:302440
SK Bioscience Co Ltd
Other Long-Term Assets
SK Bioscience Co Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Other Long-Term Assets
₩130.7B
|
CAGR 3-Years
57%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Other Long-Term Assets
₩271.5B
|
CAGR 3-Years
69%
|
CAGR 5-Years
32%
|
CAGR 10-Years
35%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Other Long-Term Assets
₩45.3B
|
CAGR 3-Years
50%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Other Long-Term Assets
₩12.4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Other Long-Term Assets
₩62.8B
|
CAGR 3-Years
109%
|
CAGR 5-Years
143%
|
CAGR 10-Years
56%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Other Long-Term Assets
₩28m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
SK Bioscience Co Ltd
Glance View
SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.
See Also
What is SK Bioscience Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
130.7B
KRW
Based on the financial report for Dec 31, 2024, SK Bioscience Co Ltd's Other Long-Term Assets amounts to 130.7B KRW.
What is SK Bioscience Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
60%
Over the last year, the Other Long-Term Assets growth was 48%. The average annual Other Long-Term Assets growth rates for SK Bioscience Co Ltd have been 57% over the past three years , 60% over the past five years .
You don't have any saved screeners yet